CJC-1295 Dosage Guide: DAC vs No DAC Clinical Protocols
Accurate CJC-1295 dosage selection is the single most critical variable in growth hormone releasing hormone (GHRH) analog research. This guide organizes documented dose ranges, administration schedules, and pharmacokinetic data for both DAC and No DAC formulations — sourced from peer-reviewed clinical studies and compounded by licensed US pharmacies.
What Is CJC-1295 and Why Does CJC-1295 Dosage Matter?
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) engineered with four amino acid substitutions to resist enzymatic degradation and extend biological activity. Originally developed by ConjuChem Biotechnologies, this 29-amino acid peptide has been studied in both animal models and healthy human subjects for its capacity to stimulate sustained growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. A landmark 2006 clinical trial published in The Journal of Clinical Endocrinology & Metabolism (Teichman et al., PMID: 16352683) established the foundational pharmacokinetic and pharmacodynamic data that informs modern CJC-1295 dose protocol design.
Selecting the correct CJC-1295 dosage is essential because the DAC (Drug Affinity Complex) and No DAC formulations produce fundamentally different pharmacokinetic profiles. DAC enables albumin binding that extends half-life to approximately 6–8 days, while the No DAC variant (also called Modified GRF 1-29) is cleared in roughly 30 minutes. These differences directly govern administration frequency, GH release patterns, and how researchers structure their dosing schedules for reproducible outcomes.
CJC-1295 DAC vs No DAC: Key Pharmacological Differences
The distinction between DAC and No DAC formulations is not merely a labeling difference — it fundamentally alters how CJC-1295 interacts with the endocrine system. Understanding these differences is the prerequisite to selecting an appropriate CJC-1295 dosage for any research protocol.
What Is the Drug Affinity Complex (DAC)?
DAC is a molecular modification that enables CJC-1295 to form a covalent bond with endogenous serum albumin after subcutaneous injection. This albumin conjugation shields the peptide from enzymatic degradation and dramatically slows renal clearance. The result is a compound that maintains bioactive concentrations in circulation for days rather than minutes, reducing the required injection frequency to once or twice weekly in study protocols.
Pharmacokinetic Comparison
Published data from Teichman et al. (2006) measured the half-life of CJC-1295 with DAC at 5.8–8.1 days in healthy subjects. By contrast, Modified GRF (1-29) — CJC-1295 without DAC — demonstrates a half-life of approximately 30 minutes. This 200-fold difference in clearance time produces two entirely different administration paradigms and GH release profiles.
GH Pulsatility Implications for CJC-1295 Dosing
A critical finding from Ionescu et al. (2006) demonstrated that CJC-1295 with DAC preserves the natural pulsatile pattern of GH secretion even during continuous stimulation. The study measured GH secretion via 20-minute blood sampling during overnight periods in healthy men and found that pulsatility was maintained while basal (trough) GH levels increased 7.5-fold, as documented in the 2006 pulsatility study (PMID: 17018654). This preserved pulsatile release pattern is a significant pharmacological advantage over exogenous GH administration.
Why Pulsatility Matters for Dose Selection
CJC-1295 No DAC dosage protocols leverage the short half-life to produce distinct GH pulses that more closely mimic physiological secretion patterns. Because the compound clears quickly, each administration creates a defined spike-and-return pattern. DAC formulations, by contrast, elevate baseline GH continuously while preserving endogenous pulses on top of that elevated baseline. Researchers must weigh whether their study design requires acute pulsatile stimulation (favoring No DAC) or sustained baseline elevation (favoring DAC) when determining CJC-1295 clinical dosing parameters.
CJC-1295 Dosage Protocols Documented in Clinical Research
Published clinical data provides the framework for CJC-1295 dose protocol design. The doses described below reflect ranges documented in peer-reviewed research involving both animal models and healthy human subjects. Researchers should note that individual protocol parameters will vary depending on study objectives and institutional guidelines.
DAC Formulation Dose Ranges in Published Studies
The Teichman et al. (2006) trial employed ascending single-dose and multi-dose designs. Subjects received single subcutaneous injections at doses of 30, 60, 125, or 250 mcg/kg. Multi-dose arms administered 30 or 60 mcg/kg either weekly or biweekly for durations of 28 to 49 days. The 30 and 60 mcg/kg dose levels were identified as the best-tolerated ranges with the most favorable safety profiles among research subjects.
| Study | Formulation | Dose Range | Frequency | Duration | Key Finding |
|---|---|---|---|---|---|
| Teichman et al., 2006 | CJC-1295 DAC | 30–60 mcg/kg | Weekly or biweekly | 28–49 days | Sustained GH elevation 6+ days |
| Teichman et al., 2006 | CJC-1295 DAC | 125–250 mcg/kg | Single dose | Single admin | Higher GH but reduced tolerability |
| Ionescu et al., 2006 | CJC-1295 DAC | 60–90 mcg/kg | Single dose | 7 days measured | Preserved GH pulsatility |
| Alba et al., 2006 | CJC-1295 (mouse model) | 2 mcg per animal | Every 24–72 hours | 5 weeks | Daily dosing normalized growth |
Sources: PMID: 16352683, PMID: 17018654, PMID: 16822960
No DAC (Modified GRF 1-29) Dose Ranges
CJC-1295 No DAC dosage ranges documented in research literature typically fall between 100 and 300 mcg per administration. Due to the 30-minute half-life, protocols generally call for once- or twice-daily subcutaneous injections. Many study designs pair Modified GRF (1-29) with a growth hormone secretagogue such as Ipamorelin to leverage complementary receptor pathways for synergistic GH release.
- Reconstitution with bacteriostatic water at a standard concentration (e.g., 3 mL per 10 mg vial) enables accurate volumetric dosing of CJC-1295 mcg per day targets.
- Lyophilized peptides should be stored frozen prior to reconstitution and refrigerated after, with no repeated freeze–thaw cycles.
- Verified purity documentation ensures dose accuracy aligns with published protocol parameters.
Combination Protocol Considerations
Research protocols that pair CJC-1295 No DAC with Ipamorelin typically administer both compounds simultaneously in a single daily injection. Published observations suggest this GHRH + GH secretagogue pairing may produce a synergistic amplification of GH release, as each peptide activates distinct receptor pathways — GHRH receptors and ghrelin receptors, respectively. Studies indicate that Ipamorelin selectively increases GH without affecting cortisol or prolactin levels, which makes it a preferred pairing compound in controlled research settings.
CJC-1295 Dosing Schedules and Cycle Length Considerations
Appropriate scheduling and cycle duration are as important as the CJC-1295 dosage itself. Research from Alba et al. (2006) in GHRH knockout mice demonstrated that administration frequency directly impacts growth normalization — daily dosing produced full normalization, while less frequent dosing showed diminished effects, as published in the American Journal of Physiology (PMID: 16822960).
Weekly vs Daily Schedules
CJC-1295 DAC formulations are typically studied on weekly or biweekly injection schedules, consistent with their 6–8 day half-life. Subjects in the Teichman et al. trial received two or three doses at weekly or biweekly intervals, with IGF-1 levels remaining above baseline for up to 28 days after multi-dose administration. No DAC protocols, conversely, utilize daily (and sometimes twice-daily) injection schedules to maintain consistent GH pulse stimulation across the study duration.
CJC-1295 Injection Timing and the Nighttime Protocol
Many CJC-1295 dosing schedule designs incorporate nighttime administration, timed to coincide with the body’s natural nocturnal GH secretion peaks. Research on GHRH analogs has shown that pre-sleep administration may enhance the amplitude of physiological GH pulses that already occur during slow-wave sleep. The CJC-1295 nighttime protocol typically involves subcutaneous injection 30–60 minutes before bedtime in a fasted state, which avoids the insulin-mediated GH suppression that occurs after food intake.
CJC-1295 Cycle Length Parameters
Published CJC-1295 cycle length parameters range from 4 weeks (as in single-study arms) to 8–12 weeks in extended protocols. Some research designs extend observation periods to 16 weeks. The Teichman et al. trial documented a cumulative effect after multiple doses, with IGF-1 remaining elevated for up to 28 days — suggesting that multi-week protocols may produce progressively greater biological responses. Researchers typically incorporate washout periods between cycles to maintain receptor sensitivity and assess baseline recovery.
⚠️ 5 Important Research Considerations for CJC-1295 Dosage
The following factors directly affect the validity and reproducibility of CJC-1295 research outcomes. Researchers must also consider the cjc1295 side effects overview to ensure comprehensive safety assessments. Variability in individual responses to the peptide can lead to unexpected outcomes. Identifying and addressing these side effects is critical for developing reliable therapeutic protocols.
- Purity Variability: Peptides sourced from unverified suppliers may contain degradation products, truncated sequences, or contaminants that alter effective dose concentrations and produce unreliable results.
- DAC/No DAC Mislabeling: Some vendors incorrectly label Modified GRF (1-29) as “CJC-1295,” creating confusion about which formulation is being used. Always confirm the molecular identity through Certificate of Analysis documentation.
- Reconstitution Errors: Incorrect bacteriostatic water volumes during reconstitution change the actual mcg-per-unit delivered, potentially invalidating dose-response data across the entire study.
- Storage Degradation: Peptide potency decreases when exposed to heat, light, or repeated freeze–thaw cycles. Degraded compounds deliver a lower effective dose than intended, skewing research outcomes.
- Clinical Trial Status: CJC-1295 reached Phase II clinical trials but was discontinued. No FDA-approved therapeutic formulation exists. All current applications are limited to research contexts under appropriate regulatory oversight.
Issue: DAC/No DAC confusion → Research Impact: Incorrect half-life assumptions lead to inappropriate dosing frequency and missed pharmacokinetic windows.
Issue: Improper storage → Research Impact: Progressive potency loss creates hidden dose reduction over the course of a multi-week protocol.
Research integrity depends on verified starting material. A 2009 proteomics study using CJC-1295 emphasized that serum biomarker changes could only be reliably attributed to the compound when pharmaceutical-grade material with confirmed identity was used.
Sourcing research-grade peptides with verified purity documentation reduces these variables significantly. View Phoenix Peptide Labs quality standards →
Multiple peer-reviewed studies have established consistent principles that guide effective CJC-1295 dose protocol design. CJC1295 treatment benefits overview outlines various advantages, including enhanced growth hormone release and improved metabolic function. Furthermore, patients often experience increased energy levels and improved muscle recovery times with this therapy. These effects contribute to the overall effectiveness of the treatment in promoting a better quality of life.
Research basis: Sackmann-Sala et al., Growth Horm IGF Res, 2009; Teichman et al., 2006
Researchers who apply verified dosing parameters with pharmaceutical-grade material consistently report more reproducible GH and IGF-1 elevation data across multi-week study designs.
How to Source High-Quality CJC-1295 Dosage Material for Your Research
Research-grade CJC-1295 requires verified identity (DAC vs No DAC confirmation), purity above 98% by HPLC analysis, a current Certificate of Analysis, and proper lyophilized storage from a licensed US compounding pharmacy. Without these quality benchmarks, published dose ranges cannot be reliably replicated in laboratory settings.
Sourcing quality directly impacts whether CJC-1295 dosage parameters from published literature can be meaningfully reproduced. The following factors represent the minimum verification standards researchers should apply.
Factor 1: Certificate of Analysis (COA) Verification
A batch-specific COA confirms the peptide’s identity, purity, and sterility for each production lot. Researchers should require COAs that include HPLC chromatograms, mass spectrometry data, and endotoxin testing results. Generic COAs that lack batch numbers or production dates should be treated as insufficient documentation for controlled research environments.
Valid COA documentation also distinguishes between DAC and No DAC formulations at the molecular level — this is essential because the two compounds require entirely different CJC-1295 dosing schedule parameters. cjc1295 dac benefits explained include its ability to enhance growth hormone levels and support muscle recovery. By understanding these advantages, users can optimize their health and fitness regimens. Additionally, exploring the differences between the two formulations can lead to more effective use of CJC-1295 and its associated benefits.
Factor 2: HPLC Purity Confirmation
High-performance liquid chromatography (HPLC) is the gold standard for peptide purity assessment. Research-grade CJC-1295 should demonstrate 98% or greater purity by HPLC analysis. Lower purity means a greater proportion of degradation products or synthesis byproducts in the vial, which effectively reduces the active dose being delivered and introduces uncontrolled variables into study results.
Factor 3: Licensed US Compounding Pharmacy Source
Peptides compounded by licensed US pharmacies operate under state board of pharmacy regulations and must follow USP standards for sterile compounding. This regulatory oversight provides a quality assurance layer that unregulated overseas suppliers cannot replicate. For CJC-1295 clinical dosing research, verified US compounding sources reduce the risk of contamination, mislabeling, and sub-potent material entering the research pipeline.
Ready to source research-grade CJC-1295 dosage material? Shop Phoenix Peptide Labs’ verified peptide catalog →
Factor 4: Cold-Chain Storage Compliance
Lyophilized CJC-1295 must be stored at -20°C prior to reconstitution and at 2–8°C after reconstitution. Suppliers who ship at ambient temperature or use inadequate cold-packing risk delivering partially degraded product. Researchers should verify that their source maintains documented cold-chain procedures from production through delivery.
Factor 5: Sterility and Endotoxin Testing
For injectable research peptides, sterility testing and endotoxin screening are non-negotiable quality parameters. Endotoxin contamination can provoke immune responses in research models that confound study endpoints. A comprehensive COA from a reputable supplier will include both USP sterility testing results and limulus amebocyte lysate (LAL) endotoxin quantification.
Phoenix Peptide Labs Quality Standards
Every CJC-1295 lot ships with full documentation to support research-grade protocols.
CJC-1295 DAC vs No DAC Dosage Comparison
The table below organizes the key pharmacological and dosing parameters for each CJC-1295 formulation side by side. These values reflect published data from the clinical studies cited throughout this guide. Researchers should use this as a reference framework, not as prescriptive guidance — individual protocol requirements will vary.
Scroll to compare| Parameter | CJC-1295 with DAC | CJC-1295 No DAC (Mod GRF 1-29) |
|---|---|---|
| Half-Life | 5.8–8.1 days | ~30 minutes |
| Study Dose Range | 30–60 mcg/kg (optimal tolerability) | 100–300 mcg per administration |
| Frequency | Weekly or biweekly | Once or twice daily |
| GH Release Pattern | Sustained baseline elevation + preserved pulses | Acute pulsatile spikes per injection |
| IGF-1 Elevation Duration | 9–11 days (single); up to 28 days (multi) | Hours per dose; cumulative over cycle |
| Common Pairing | Used as standalone in published trials | Often combined with Ipamorelin |
| Injection Timing | Any time (long half-life makes timing less critical) | Pre-sleep / fasted state preferred |
| Typical Cycle Length | 4–12 weeks | 8–12 weeks (up to 16) |
Who Uses CJC-1295 in Research?
CJC-1295 research spans multiple disciplines and procurement contexts. The following profiles represent common scenarios where accurate dosage documentation and verified purity are critical for study success.
The Academic Endocrinology Lab
University research teams studying GH/IGF-1 axis dynamics in animal models need consistent, verified CJC-1295 dosage material to produce publishable, reproducible dose-response data across extended study timelines.
The Independent Researcher Prioritizing Purity
Solo investigators and small labs often lack the in-house analytical equipment to verify peptide identity. They rely entirely on supplier documentation to confirm that the CJC-1295 formulation (DAC vs No DAC) matches their protocol requirements.
The Research Team Scaling a Protocol
Teams transitioning from pilot studies to larger-scale protocols need reliable supply chains that can deliver consistent CJC-1295 dosage material at volume without quality variation between shipments.
Frequently Asked Questions
Published clinical research utilized doses of 30–60 mcg/kg for CJC-1295 with DAC and 100–300 mcg per administration for the No DAC formulation. The Teichman et al. (2006) trial identified 30 and 60 mcg/kg as the best-tolerated dose levels for DAC formulations in healthy subjects, with dose-dependent increases in GH and IGF-1 across all studied ranges. Exact dosing parameters should be determined by institutional research protocols and study-specific objectives. For sourcing questions or documentation requests, contact our team.
The primary difference is administration frequency driven by half-life. CJC-1295 with DAC has a 6–8 day half-life, supporting weekly or biweekly dosing. CJC-1295 without DAC (Modified GRF 1-29) clears in approximately 30 minutes, requiring once- or twice-daily administration to maintain research-relevant GH stimulation. Researchers should select the formulation that aligns with their study’s GH release pattern objectives — sustained baseline elevation (DAC) or acute pulsatile stimulation (No DAC). For technical specifications, contact our team.
Published protocols range from 4 to 12 weeks, with some extended designs running up to 16 weeks. The Teichman et al. study documented IGF-1 remaining elevated for up to 28 days after multi-dose administration, suggesting cumulative biological effects over longer protocols. Washout periods between cycles are standard practice in research design to assess baseline recovery and maintain receptor sensitivity. For documentation on cycle-specific product availability, contact our team.
Research-grade CJC-1295 should demonstrate ≥98% purity as confirmed by HPLC analysis. Lower purity levels introduce degradation byproducts and synthesis impurities that alter the effective dose being administered, rendering dose-response data unreproducible. Batch-specific Certificates of Analysis with HPLC chromatograms, mass spectrometry confirmation, and endotoxin screening represent the minimum documentation standard for controlled research environments. For purity documentation, contact our team.
Need technical specifications or purity documentation? Contact Phoenix Peptide Labs directly →
CJC-1295 No DAC is frequently studied alongside Ipamorelin, a selective GH secretagogue. Research suggests these compounds act on complementary receptor pathways — GHRH receptors and ghrelin receptors — potentially producing synergistic GH release. Ipamorelin has been documented to selectively increase GH without elevating cortisol, ACTH, or prolactin, which makes it a preferred research pairing. Combination protocols typically administer both compounds at the same time in a single daily injection event. For sourcing questions, contact our team.
Lyophilized CJC-1295 should be stored at -20°C until reconstitution. Standard reconstitution uses bacteriostatic water — typically 2–3 mL per vial — injected gently against the vial wall to avoid damaging the peptide structure. After reconstitution, the solution should be refrigerated at 2–8°C and used within 4–6 weeks. Repeated freeze–thaw cycles degrade peptide integrity and reduce effective potency, which compromises dose accuracy throughout the study. For storage protocol guidance, contact our team.
CJC-1295 is not approved by the FDA for human therapeutic use. The compound reached Phase II clinical trials for lipodystrophy and growth hormone deficiency but development was discontinued. All current applications of CJC-1295 are restricted to research and laboratory use under appropriate regulatory frameworks. Phoenix Peptide Labs products are sold strictly for laboratory and research purposes. For regulatory questions, contact our team.
CJC-1295 injection timing is significant primarily for No DAC formulations due to the short half-life. Research on GHRH analogs indicates that pre-sleep administration in a fasted state may capitalize on natural nocturnal GH secretion patterns. Administering CJC-1295 after a meal can blunt GH release because elevated insulin suppresses GH secretion. For DAC formulations, timing is less critical because the extended half-life maintains continuous receptor stimulation regardless of administration time. For protocol design assistance, contact our team.
⚗️ Research Use Disclaimer
All content on this page is intended for informational and research purposes only. The compounds discussed are not approved by the FDA for human therapeutic use. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed medical professional before making any health-related decisions. Phoenix Peptide Labs products are sold strictly for laboratory and research use.